Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Apriso CAP · 1 trial · 1 indication
Maximum observed plasma concentration levels used for descriptive analysis
| Arm | Type | Description |
|---|---|---|
| Apriso 0.375G ER CAP | EXPERIMENTAL | Apriso 0.375G ER Cap |
| APRISO 375 mg extended-release capsules | ACTIVE_COMPARATOR | APRISO 375 mg ER cap |
| Name | Type | Description |
|---|---|---|
| Apriso 0.375G ER CAP | DRUG | ER capsule |
| APRISO 375 mg extended-release capsules | DRUG | 375 mg extended-release capsules |
Inclusion Criteria: * Healthy male or female, at least 18 years of age * Body mass index (BMI) between18.5 and below 32.0 kg/m2 (inclusive) * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, ECG and labo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 10 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Upadacitinib |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Tulisokibart |
| Pfizer Inc. | PFE | 8 | PHASE3 | Etrasimod |
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Filgotinib |
| Abivax SA Sponsored ADR | ABVX | 2 | PHASE3 | ABX464 |
| Bristol-Myers Squibb Company | BMY | 5 | PHASE2 | Ozanimod |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Palatin Technologies, Inc. | PTN | 1 | PHASE2 | PL8177 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | GSK4528287 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | XmAb942 |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE2 | 627 |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Apriso CAP is an investigational small molecule being developed for ulcerative colitis, a form of inflammatory bowel disease. It is a capsule formulation of Apriso 375 mg being studied in healthy volunteers as part of a Phase 1 clinical trial. The drug is not yet approved and remains in clinical development.
Apriso CAP is being developed by Bausch Health Companies Inc., traded on the New York Stock Exchange under the ticker BHC. The company is conducting clinical research on this formulation for ulcerative colitis, with the drug currently in Phase 1 development.
Apriso CAP is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under study for ulcerative colitis.
Apriso CAP has one completed clinical trial, NCT03327558, a randomized, double-blind, active-controlled Phase 1 study comparing Apriso 375 mg to the approved Apriso 375 mg capsules in healthy male and female subjects. The trial enrolled 60 participants in the United States.
Apriso CAP is a capsule formulation of Apriso 375 mg, studied in a Phase 1 trial against the approved Apriso 375 mg capsules. While related, Apriso CAP is an investigational version being evaluated for ulcerative colitis, whereas the approved Apriso capsules are already marketed.